Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study.

作者信息

Plaxe Steven C, Blessing John A, Morgan Mark A, Carlson John

机构信息

Department of Reproductive Medicine, Division of Gynecologic Oncology, University of California-San Diego Medical Center, 402 Dickinson Street, San Diego, CA 92103-8433, U.S.A.

出版信息

Am J Clin Oncol. 2002 Feb;25(1):45-7. doi: 10.1097/00000421-200202000-00009.

The Gynecologic Oncology Group performed a Phase II study to determine the response rate of pyrazoloacridine (PZA) in patients with platinum-resistant ovarian cancer. PZA was administered at a dose of 750 mg/m2 intravenously over 3 hours every 3 weeks. Among 24 evaluable patients, there was 1 (4.2%) complete and 1 (4.2%) partial response. The major toxicities were hematologic. With the dose and schedule used, PZA had only modest activity in this population.